Merck combination treatment for lung cancer fails late-stage study

Merck (MRK.N) said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.

This is the latest trial failure studying the combination of Merck's blockbuster drug Keytruda and AstraZeneca-partnered (AZN.L)Lynparza. It previously failed a trial evaluating it as a treatment for a type of prostate cancer, opens new tab.